DH
Therapeutic Areas
Formosa Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| APP13007 | Inflammation and pain after ocular surgery | Approved |
| APP13002 | Bacterial conjunctivitis, keratitis, blepharitis, Meibomian Gland Dysfunction | Preclinical/Clinical |
| TSY-110 | HER2-positive cancers (ADC biosimilar) | Development |
| TSY-120 | HER2-positive cancers (ADC biosimilar) | Development |
| TSY-310 | Solid tumors (bispecific ADC) | Development |
Leadership Team at Formosa Pharmaceuticals
DC
Dr. Chen-Yu Cheng
Chairman and Founder
DJ
Dr. Jo Shen
Board Director
DW
Dr. Weng-Foung Huang
Board Director